Page 16 - SaxoCell Annual Report22/23

Patents: Since the beginning of the first SaxoCell implementation phase, nine patent
applications have been filed, one by the CAR-NK4.0 project, one by the NK4Therapy
project, five by the xMac project and two by the OPTIX project. Another five patents were
filed with the support of SaxoCell employees. In addition, one more patent from OPTIX is
pending.

Publications: In the SaxoCell context and with the assistance of SaxoCell PIs and
collaborators, numerous, high-profile publications have been published in journals such
as: Nature Communication, Frontiers in Immunology, Frontiers in Pharmacology, Blood,
JAMA Oncology, Lancet Hematology and Leukemia.

Press releases: Several SaxoCell-related press releases were published during the
reporting period, e.g. from Leipzig University Hospital "First in Europe - All CAR-T cell
therapy products available in Germany for cancer patients will be available at Leipzig
University Hospital in the near future" and from Chemnitz Hospital "Chemnitz Hospital
introduces CAR-T cell therapy". In addition, announcements were published on EU grants
acquired and the Seamless Therapeutics spin-off.

Visibility: The visibility of the cluster is strengthened by a series of public lectures and
workshops, cooperation with partners from industry and public relations, participation in
national and international conferences and trade fairs, our SaxoCell website as well as
social media appearances.

Additional funding: In the cluster, additional funding was obtained with the participation
of SaxoCell members, e.g. the GO-Bio initial funding for the xMac project, EU funding for
Leipzig and Dresden projects, as well as another BMBF funding for a project by Michael
Hudecek in cooperation with the Fraunhofer IZI.

11